Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk
- 1 September 2007
- journal article
- treatment related-complications
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (25), 3871-3876
- https://doi.org/10.1200/jco.2007.12.0832
Abstract
Purpose The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women. Patients and Methods Data from the Surveillance, Epidemiology, and End Results-Medicare linked database were used for women diagnosed with nonmetastatic breast cancer from 1992 to 2002. The primary end point was a claim with an inpatient or outpatient diagnosis of AML (International Classification of Diseases ninth revision, codes 205 to 208), comparing patients treated with and without adjuvant chemotherapy, and by differing chemotherapy regimens. The cumulative hazard of AML was estimated using the Kaplan-Meier method. Cox proportional hazards models were used to determine factors independently associated with the development of AML. Results In this observational study, there were 64,715 patients: 10,130 received adjuvant chemotherapy and 54,585 did not. The median patient age was 75.6 years (range, 66 to 104 years). The mean follow-up was 54.8 months (range, 13 to 144 months). The absolute risk of developing AML at 10 years after any adjuvant chemotherapy for breast cancer was 1.8% versus 1.2% for women who had not received chemotherapy. The adjusted hazard ratio for AML with adjuvant chemotherapy versus none was 1.53 (95% CI, 1.14 to 2.06). Granulocyte colony-stimulating factor (G-CSF) within the first year of diagnosis did not convey a significantly increased risk of AML (hazard ratio, 1.14; 95% CI, 0.67 to 1.92). Conclusion There is a small but real increase in AML after adjuvant chemotherapy for breast cancer in older women. This study may underestimate the true incidence because myelodysplastic syndrome cannot be identified through claims. G-CSF use within the first year of diagnosis does not convey an increased risk of AML in older women.Keywords
This publication has 12 references indexed in Scilit:
- Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?JNCI Journal of the National Cancer Institute, 2007
- Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast CancerJournal of Clinical Oncology, 2007
- Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast CancerJournal of Clinical Oncology, 2006
- Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and CyclophosphamideJournal of Clinical Oncology, 2005
- Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study GroupAnnals Of Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Breast Cancer Treatment Guidelines in Older WomenJournal of Clinical Oncology, 2005
- Risk for the Development of Treatment-Related Acute Myelocytic Leukemia and Myelodysplastic Syndrome Among Patients with Breast Cancer: Review of the Literature and the National Surgical Adjuvant Breast and Bowel Project ExperienceClinical Breast Cancer, 2003
- Development of a comorbidity index using physician claims dataJournal of Clinical Epidemiology, 2000
- Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast CancerNew England Journal of Medicine, 1992